Roloff, G., Faramand, R., Aldoss, I., Kopmar, N., Schwartz, M., Dekker, S., … Muffly, L. (2023). Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL. In Journal of Clinical Oncology (Vol. 16_suppl, pp. 7001–7001). Chicago, IL: American Society of Clinical Oncology.

Roloff, Gregory, Rawan Faramand, Ibrahim Aldoss, Noam Kopmar, Marc Schwartz, Simone Dekker, Chenyu Lin, et al. “Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.” In Journal of Clinical Oncology, 16_suppl:7001–7001. American Society of Clinical Oncology, 2023.

Roloff G, Faramand R, Aldoss I, Kopmar N, Schwartz M, Dekker S, et al. Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL. In: Journal of Clinical Oncology. American Society of Clinical Oncology; 2023. p. 7001–7001.

Roloff, Gregory, et al. “Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.” Journal of Clinical Oncology, vol. 16_suppl, no. 41, American Society of Clinical Oncology, 2023, pp. 7001–7001.

Roloff G, Faramand R, Aldoss I, Kopmar N, Schwartz M, Dekker S, Lin C, Tracy S, Vilchez S, Dykes K, O’Connor T, Ahmed M, Gupta V, Ladha A, Tsai S, Leonard J, Galal A, Cassaday R, Shah B, Muffly L. Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL. Journal of Clinical Oncology. American Society of Clinical Oncology; 2023. p. 7001–7001.